What is Cavion?
Headquartered in Charlottesville, Virginia, and Cambridge, Massachusetts, Cavion operates at the intersection of neuroscience and drug discovery. The company specializes in the development of small-molecule therapies designed to modulate T-type calcium channels, which are critical for maintaining the brain's natural electrical rhythms. By targeting these channels, Cavion addresses a spectrum of debilitating conditions, including essential tremor, Parkinson's disease-related tremors, neuropathic pain, and epilepsy with absence seizures.
The company's market position is defined by its focus on high-unmet-need neurological disorders. By leveraging a sophisticated understanding of ion channel biology, Cavion has transitioned from a research-intensive startup to a specialized entity capable of delivering transformative clinical outcomes. Their portfolio represents a significant advancement in precision medicine, aiming to restore neurological homeostasis in patients who have historically lacked effective treatment options.
How much funding has Cavion raised?
Cavion has raised a total of $31.5M across 2 funding rounds:
Private Equity
$5M
Series A
$26.5M
Private Equity (2015): $5M, investors not publicly disclosed
Series A (2017): $26.5M led by Lilly Ventures, Novartis Venture Fund, and Enso Ventures
Key Investors in Cavion
Lilly Ventures
A venture capital firm rooted in the scientific tradition of Eli Lilly, focusing on life science innovations and providing both financial and intellectual resources to accelerate growth.
Novartis Venture Fund
The venture arm of a global pharmaceutical leader, specializing in the research and development of innovative medications across diverse therapeutic areas.
Enso Ventures
A venture capital firm that targets high-growth technology and biotech companies, providing capital and leadership expertise to promote commercial development.
What's next for Cavion?
Following its acquisition by Jazz Pharmaceuticals, Cavion's strategic focus has shifted toward the integration of its T-type calcium channel platform into a larger, global commercial infrastructure. The capital previously raised has served as the foundation for this transition, enabling the acceleration of clinical trials and the refinement of therapeutic candidates. Moving forward, the focus remains on the successful clinical validation of their lead assets and the potential for these therapies to redefine the standard of care in neurology. The synergy between Cavion's specialized research capabilities and the operational scale of its parent company suggests a high probability of long-term commercial success in the competitive landscape of central nervous system therapeutics.
See full Cavion company page
